Table 2. Univariate analyses for relapse-free survival and overall survival.
|
Relapse-free survival |
Overall survival |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | N | Median (months) | HR | 95% CI | P | Median (months) | HR | 95% CI | P |
|
Mutational status | |||||||||
| All wt | 137 | 14.4 | 1 | — | — | 63.3 | 1 | — | — |
| BRAF mut | 12 | 5.7 | 2.13 | 1.20–7.31 | 0.019 | 22.6 | 3.07 | 2.12–22.94 | 0.002 |
| RAS mut | 160 | 11.0 | 1.22 | 0.94–1.58 | 0.142 | 42.0 | 1.47 | 1.05–2.07 | 0.025 |
|
Sex | |||||||||
| Male | 192 | 12.2 | 1 | — | — | 53.8 | 1 | — | — |
| Female | 117 | 10.7 | 0.98 | 0.75–1.28 | 0.878 | 40.7 | 1.19 | 0.85–1.68 | 0.313 |
|
Age | |||||||||
| <65 years | 177 | 11.7 | 1 | — | — | 52.8 | 1 | — | — |
| ⩾65 years | 132 | 11.4 | 1.09 | 0.84–1.41 | 0.526 | 46.6 | 1.17 | 0.84–1.64 | 0.349 |
|
ECOG PS | |||||||||
| 0 | 267 | 12.2 | 1 | — | — | 54.0 | 1 | — | — |
| 1–2 | 42 | 9.4 | 1.38 | 0.96–2.16 | 0.076 | 26.5 | 1.95 | 1.42–3.95 | 0.001 |
|
Primary tumour site | |||||||||
| Left colon | 138 | 12.0 | 1 | — | — | 57.3 | 1 | — | — |
| Right colon | 87 | 10.7 | 1.23 | 0.91–1.69 | 0.179 | 35.5 | 1.59 | 1.10–2.45 | 0.017 |
| Rectum | 82 | 12.6 | 1.04 | 0.76–1.43 | 0.794 | 61.1 | 0.95 | 0.63–1.43 | 0.804 |
|
Liver only | |||||||||
| Yes | 281 | 12.6 | 1 | — | — | 53.8 | 1 | — | — |
| No | 28 | 7.5 | 1.92 | 1.41–4.20 | 0.001 | 25.5 | 2.22 | 1.57–6.43 | 0.001 |
|
Unilobar mts | |||||||||
| Yes | 198 | 15.1 | 1 | — | — | 61.1 | 1 | — | — |
| No | 111 | 7.9 | 1.55 | 1.22–2.13 | 0.0009 | 34.8 | 1.59 | 1.16–2.33 | 0.006 |
|
Time to mts | |||||||||
| Metachronous | 101 | 15.1 | 1 | — | — | 56.8 | 1 | — | — |
| Synchronous | 208 | 10.4 | 1.48 | 1.11–1.89 | 0.006 | 48.7 | 1.30 | 0.91–1.82 | 0.158 |
|
Resection outcome | |||||||||
| R0 | 258 | 14.2 | 1 | — | — | 61.1 | 1 | — | — |
| R1/R2-Expl. Lapar. | 51 | 6.3 | 2.39 | 2.27–5.44 | <0.0001 | 21.6 | 3.21 | 3.66–10.85 | <0.0001 |
|
Primary lymph nodes | |||||||||
| No | 96 | 17.7 | 1 | — | — | 56.8 | 1 | — | — |
| Yes | 206 | 10.4 | 1.58 | 1.17–2.00 | 0.002 | 51.9 | 1.35 | 0.94–1.89 | 0.107 |
|
DFI <12 months | |||||||||
| Yes | 242 | 10.7 | 1 | — | — | 47.0 | 1 | — | — |
| No | 67 | 17.1 | 0.67 | 0.52–0.93 | 0.015 | 61.1 | 0.80 | 0.54–1.21 | 0.312 |
|
>1 liver mts | |||||||||
| No | 132 | 16.8 | 1 | — | — | 69.3 | 1 | — | — |
| Yes | 173 | 8.8 | 1.76 | 1.36–2.27 | <0.0001 | 36.0 | 1.84 | 1.30–2.49 | 0.0005 |
|
Mts diameter >5 cm | |||||||||
| No | 231 | 11.7 | 1 | — | — | 56.8 | 1 | — | — |
| Yes | 62 | 11.2 | 1.13 | 0.82–1.58 | 0.437 | 52.7 | 1.19 | 0.79–1.85 | 0.396 |
|
CEA>200 ng ml−1 | |||||||||
| No | 212 | 11.0 | 1 | — | — | 46.6 | 1 | — | — |
| Yes | 9 | 9.0 | 1.21 | 0.54–2.82 | 0.620 | 17.5 | 2.40 | 1.24–12.11 | 0.021 |
|
Clinical risk scorea | |||||||||
| Low | 138 | 16.6 | 1 | — | — | 58.6 | 1 | — | — |
| High | 137 | 8.6 | 1.75 | 1.35–2.35 | <0.0001 | 35.5 | 1.65 | 1.16–2.35 | 0.005 |
Abbreviations: CI=confidence interval; DFI=disease-free interval; Expl. Lapar.=explorative laparotomy; HR=hazard ratio; mts=metastasis; mut=mutant; N=number; PS=performance status; wt=wild-type.
a
Clinical risk score is defined as previously described by Fong et al (1999): patients with 0 to 2 risk features were categorised as ‘low risk', while those with 3 to 5 features as ‘high risk'. Bold entries indicate significant results.